Daily Stock Analysis, GTXI, GTX Inc, priceseries

GTX Inc. Daily Stock Analysis
Stock Information
Open
1.18
Close
1.20
High
1.28
Low
1.16
Previous Close
5.92
Daily Price Gain
-4.71
YTD High
17.92
YTD High Date
Mar 7, 2019
YTD Low
1.16
YTD Low Date
Jun 28, 2019
YTD Price Change
-4.80
YTD Gain
-80.00%
52 Week High
179.20
52 Week High Date
Sep 13, 2018
52 Week Low
1.16
52 Week Low Date
Jun 28, 2019
52 Week Price Change
-103.24
52 Week Gain
-98.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 1. 2017
34.72
Mar 2. 2017
37.31
1 Trading Days
7.46%
Link
LONG
Sep 6. 2017
46.62
Sep 14. 2017
50.08
6 Trading Days
7.43%
Link
LONG
Nov 9. 2017
60.69
Nov 16. 2017
68.08
5 Trading Days
12.18%
Link
LONG
Nov 20. 2017
77.84
Dec 6. 2017
85.44
11 Trading Days
9.77%
Link
LONG
Jan 11. 2018
80.92
Feb 2. 2018
98.27
15 Trading Days
21.44%
Link
LONG
Mar 2. 2018
117.67
Mar 13. 2018
141.75
7 Trading Days
20.47%
Link
LONG
Aug 27. 2018
139.23
Sep 17. 2018
160.18
14 Trading Days
15.05%
Link
Company Information
Stock Symbol
GTXI
Exchange
NasdaqCM
Company URL
http://www.gtxinc.com
Company Phone
901-523-9700
CEO
Marc Steven Hanover
Headquarters
Tennessee
Business Address
175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS, TN 38103
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001260990
About

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

Description

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company is developing selective androgen receptor modulators to treat a range of serious diseases, including breast cancer, stress urinary incontinence, and Duchenne muscular dystrophy; and selective androgen receptor degrader for the treatment of castration resistant prostate cancer. Its products include enobosarm, a Phase II open-label proof-of-concept clinical trial for patients with advanced AR positive TNBC and ER positive/AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.